EMFAT
APLS

Emerald Mutual Fund Advisers Trust’s Apellis Pharmaceuticals APLS Stock Holding History

Emerald Mutual Fund Advisers Trust’s Portfolio APLS Stock Details APLS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-1,020
Closed -$60K – 225
2024
Q1 		$60K Buy
+1,020
New +$65K ﹤0.01% 227

Other funds holding APLS

Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.06B AUM 215.32% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Emerald Mutual Fund Advisers Trust's APLS Position: Q2 2024 in Review

Emerald Mutual Fund Advisers Trust sold out of Apellis Pharmaceuticals (APLS) in Q2 2024, closing a stake of 1,020 shares — an estimated $60K sold.

Emerald Mutual Fund Advisers Trust first reported a position in APLS in Q1 2024 and held it in 1 quarter. The position peaked at $60K in Q1 2024. 263 funds tracked by Wall St. Rank hold APLS as of Q2 2024.

  • Emerald Mutual Fund Advisers Trust reported no remaining Apellis Pharmaceuticals position as of Q2 2024 after selling out during the quarter.
  • Emerald Mutual Fund Advisers Trust sold 1,020 Apellis Pharmaceuticals shares in Q2 2024, an estimated $60K.
  • Emerald Mutual Fund Advisers Trust first reported a position in Apellis Pharmaceuticals in Q1 2024 and held it in 1 quarter.
  • Emerald Mutual Fund Advisers Trust's Apellis Pharmaceuticals position peaked at $60K in Q1 2024.
  • 263 funds tracked by Wall St. Rank held Apellis Pharmaceuticals as of Q2 2024.

Based on Emerald Mutual Fund Advisers Trust's 13F filing for Q2 2024, filed 6 Aug 2024.